Animal Health Innovation Asia 2019 will be held on November 6th and 7th at Hotel Westin Tokyo. We, AHRMS, Inc., are supporting the event as “Consulting Partner” to fix the program, introduce Japanese start-ups and new technologies to multi-national animal health manufacturers and facilitate those companies to enter Japanese animal health markets.
In progress: ■Applications of oral presentations by Japanese TLOs and Start-ups (until June 25th) ■Recruiting of Sponsor companies
Program ■Dr. Ken Noda of NVAL, JMAFF ■Dr. Masato Sakai of JVMA ■Dr. Hiroshi Oishi of JVPA
Zoetis received three approvals from the Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF) in 2018, bolstering its position as the firm with the most new products in Japan over the last 10 years.
The JMAFF approved 14 new animal drugs in 2018. These products included five antimicrobials, four pharmaceuticals, three biologicals and two antiparasitics. There were eight approvals for livestock and six authorizations for companion animals.
The number of JMAFF approvals is down by one in comparison to 2017’s total.
Regarding marketing approvals for new animal health products in Japan between 2009 and 2018, Tokyo-based animal health consultancy AHRMS said Zoetis had received the most.
The president of AHRMS – Yuki Ujimasa – told Animal Pharm: “The largest number of approvals was gained by Zoetis (37) followed by Kyoritsu Seiyaku (30), MSD Animal Health (18), Kyoto Biken (18), KM Biologics (17.5), Novartis Animal Health (11), Boehringer Ingelheim Animal Health (11), Merial (10), Nisseiken (9), Elanco (8), DS Pharma Animal Health (8), Zenoaq (6), Bayer Animal Health (5) and Meiji Seika Animal Health (5).”
Of these approvals, 100 were for international businesses and 93.5 for domestic companies.
Dr Ujimasa explained: “The number includes pharmaceuticals, biologicals and diagnostics for dogs, cats, cattle, swine, poultry and fish. Generics and claim extensions are excluded. Approvals for a new species is counted as ‘1’. A product of co-registration with two companies is counted as ‘0.5’.”